My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

131.26 -0.65 (-0.49%)

Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

51 52 Next >

How Is The Market Feeling About Novartis? ↗

August 15, 2025

Via Benzinga

2 Dividend Stocks to Buy and Hold ↗

August 15, 2025

These stocks look like they can weather almost any storm.

Via The Motley Fool

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Emerges as a Top Pick for Value Investors with Strong Fundamentals and Attractive Valuation ↗

August 15, 2025

Novartis AG-SPONSORED ADR (NVS) is a top pick for value investors, offering solid fundamentals, strong profitability, and a 3.76% dividend yield, all at an attractive valuation.

Via Chartmill

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate ↗

August 13, 2025

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease.

Via Benzinga

P/E Ratio Insights for Novartis ↗

August 12, 2025

Via Benzinga

Novartis Rides Bullish Retail Mood, Roche Faces Gloom Amid Swiss-US Trade Concerns ↗

August 11, 2025

Via Stocktwits

Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium ↗

August 06, 2025

Via Stocktwits

Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder ↗

August 12, 2025

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.

Via Benzinga

This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point ↗

August 11, 2025

Truist, however, kept a ‘Buy’ rating on the shares.

Via Stocktwits

Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well ↗

August 11, 2025

Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.

Via Stocktwits

Novartis' Investigational Drug Aces Two Pivotal Trials For Chronic Disease Impacting Tears, Saliva ↗

August 11, 2025

Novartis' ianalumab showed significant disease activity improvement in two Phase 3 Sjögren's trials, supporting plans for global health authority filings.

Via Benzinga

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% ↗

August 08, 2025

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat.

Via Benzinga

2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever ↗

August 08, 2025

These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world.

Via The Motley Fool

Topics ETFs

PTCT Earnings Beat but Sales Drop 4% ↗

August 07, 2025

Via The Motley Fool

Topics Earnings

Monte Rosa (GLUE) Q2 Revenue Jumps 394% ↗

August 07, 2025

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Schrödinger (SDGR) Q2 2025 Earnings Transcript ↗

August 06, 2025

Via The Motley Fool

Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful ↗

August 06, 2025

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.

Via Stocktwits

Topics Earnings

Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal ↗

August 06, 2025

The company is focused on treatments for forms of muscular dystrophy.

Via Investor's Business Daily

Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave

August 04, 2025

In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

Hazelden Betty Ford Foundation Appoints Four New Members to Its Board of Trustees

July 31, 2025

Center City, Minnesota--(Newsfile Corp. - July 31, 2025) - Hazelden Betty Ford Foundation, the nation's leading nonprofit system of addiction...

Via Newsfile

15 regions chosen for groundbreaking effort to reduce cardiovascular disease

July 28, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs ↗

July 25, 2025

US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon.

Via Benzinga

Topics Economy Government World Trade

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗

July 25, 2025

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.

Via Benzinga

U.S. Current-Account Deficit Widens to $450 Billion Amid Trade Imbalances and Energy Imports

July 25, 2025

The United States current-account deficit expanded sharply to $450 billion in the first half of 2025, marking a renewed widening of the country's financial shortfall with the rest of the world. This...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

NOVARTIS AG-SPONSORED ADR (NYSE:NVS): A Top Dividend Stock with Strong Profitability and Financial Stability ↗

July 25, 2025

NOVARTIS AG (NVS) is a top dividend stock with a 3.76% yield, strong profitability, and financial stability, making it ideal for income-focused investors.

Via Chartmill

The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies. ↗

July 24, 2025

Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues.

Via Investor's Business Daily

Topics Death Workforce

Screening for cardiovascular disease marker in community health centers may reduce risk

July 23, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗

July 22, 2025

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.

Via Benzinga

Topics Government

Highest Ever for This International Stock ETF -- But Analysts Say It Has Room to Run ↗

July 22, 2025

Via The Motley Fool

Topics ETFs World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

51 52 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition